AD

Eczema Society of Canada is itching for change this awareness month

Retrieved on: 
Wednesday, November 1, 2023
FAAD, Patient, Child, Dermatitis, AD, Irritation, Itch, Life, ESC, Skin, FRCPC, Quality of life, Learning, Caregiver, Bleeding, Sleep, Blood, Atopic dermatitis, Mental health, Nursing, MD

November is Eczema Awareness Month, and members of the eczema community are being encouraged to raise their voices to affect change.

Key Points: 
  • November is Eczema Awareness Month, and members of the eczema community are being encouraged to raise their voices to affect change.
  • TORONTO, Nov. 1, 2023 /CNW/ - November is Eczema Awareness Month, and Eczema Society of Canada (ESC) is working to change perceptions around eczema with its #ItchingForChange initiative.
  • Eczema can impact all parts of daily life for sufferers and their families by affecting sleep, productivity at work/school, and relationships.
  • For anyone interested in learning more about eczema and helping to improve awareness and understanding this awareness month, visit eczemahelp.ca/itchingforchange .

ConcertAI's TeraRecon Broadens Collaboration with Avicenna.AI to Offer AI-Driven Care Coordination for Pulmonary Embolism and Aortic Disease

Retrieved on: 
Wednesday, November 1, 2023
FDA, Intelligence, Triage, AD, Radiology, PACS, AAA, Rupture, Health, Cardiology, Pulmonary embolism, Thoracic aortic aneurysm, Abdominal aortic aneurysm, PE, TAA, Machine learning, Neurology, Aortic dissection, CINA, Algorithm, Avicenna, Deep learning, Patient, Stenosis, Medical device, EU

Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD).

Key Points: 
  • Together, they will provide global solutions that leverage artificial intelligence to enhance care coordination and improve patient triage for individuals afflicted with pulmonary embolism (PE) and aortic dissection (AD).
  • This collaboration aims to expedite clinical decision-making and optimize patient care for these critical medical conditions.
  • "We are excited to empower TeraRecon users worldwide with our groundbreaking AI-driven solutions for the care coordination of pulmonary embolism and aortic dissection," said Cyril Di Grandi, Chief Executive Officer of Avicenna.AI.
  • We eagerly anticipate extending the benefits of our pulmonary embolism and aortic dissection triage tools to the emergency room and beyond."

Netwrix Continues to Enhance and Simplify Data Security, Both on Premises and in the Cloud

Retrieved on: 
Monday, October 30, 2023
Online, AD, Multi, MacOS, Active Directory, PAM, MSP, MFA, Organization, IAM, Microsoft Windows, Risk, Identity, LSASS, Member of the Scottish Parliament, Software as a service, Risk management, Medical imaging, Online shopping, Netwrix, Entra

FRISCO, Texas, Oct. 30, 2023 /PRNewswire/ -- Netwrix, a cybersecurity vendor that makes data security easy, has released new versions of eight products since March 2023. The enhancements further help customers reduce the risk of breaches and limit the impact of attacks by empowering IT teams to fortify the security posture and to promptly detect and respond to threats and recover from them faster and with less effort. 

Key Points: 
  • FRISCO, Texas, Oct. 30, 2023 /PRNewswire/ -- Netwrix, a cybersecurity vendor that makes data security easy, has released new versions of eight products since March 2023.
  • - Netwrix StealthINTERCEPT now accelerates detection of LSASS access blocking by third-party software to enable swift recognition and resolution of the situation.
  • - Netwrix Usercube further reduces the attack surface by removing direct role assignments that are redundant given the role model's rules.
  • To learn more about how to leverage Netwrix solutions, register for Netwrix Connect , our user and partner conference scheduled for March 2024 in Orlando, Florida.

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

Retrieved on: 
Friday, October 27, 2023
Mevalonate pathway, AD, Inflammation, International development, Doctor of Philosophy, Protein, TPD, Pharmacokinetics, Hidradenitis suppurativa, Sanofi, Safety, Therapy, Patient, Pharmaceutical industry, HS, MD, IRAK4

The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS.

Key Points: 
  • The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS.
  • Kymera’s partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD.
  • Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million.
  • Dosing of the first patient in the AD trial will also generate a milestone payment to Kymera.

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Retrieved on: 
Thursday, October 26, 2023
Fillit, Plasma, AD, Astrocyte, HD, MD, Conference, Brain, Dementia, Inflammation, Clinical trial, Encephalitis, Disease, Glial fibrillary acidic protein, Risk, Antibody, GFAP, Blood, Patient, Pharmaceutical industry, Medical imaging

The company now reports data indicating that pepinemab treatment significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, providing further evidence of the drug’s potential to reverse harmful astrocyte activation and brain inflammation.

Key Points: 
  • The company now reports data indicating that pepinemab treatment significantly reduced blood levels of GFAP, a biomarker of reactive astrocytes, providing further evidence of the drug’s potential to reverse harmful astrocyte activation and brain inflammation.
  • Astrocytes are key regulatory cells in the brain that, under conditions of brain injury or disease, switch from their normal supportive physiological functions to inflammatory activity that is believed to aggravate damage to brain tissue.
  • A committee convened by the Alzheimer’s Association has recently recommended GFAP as a leading blood-based biomarker of astrocytic activation and brain inflammation in AD.
  • Given the many physiological parallels between neurodegenerative processes in HD and AD, we believe that similar biological effects of pepinemab treatment are likely in the two indications.

NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Retrieved on: 
Thursday, October 26, 2023
Week, Research, MRI, AD, IND, Mini–Mental State Examination, IV, Glial fibrillary acidic protein, Therapy, CSF, ADAS, Dispute board, Cell, Protein, Clinical trial, PET, Poster, ADAS-Cog, Traffic barrier, Cerebrospinal fluid, NK, Alzheimer's disease, GFAP, MMSE, Classification, Safety, Patient, Medical device, Pharmaceutical industry, Medical imaging, Hospital Angeles Tijuana

SANTA ANA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today presented a poster with Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (AD) at the Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting in Boston, MA.

Key Points: 
  • The severity of AD was based on the baseline Clinical Dementia Rating-Sum of Boxes, or CDR-SB score.
  • The primary endpoint was safety and secondary endpoints included changes in cognitive assessments and biomarker levels.
  • We are very excited to begin this next phase in hopes of establishing an entirely new treatment paradigm for more advanced patients."
  • *Data at Week 22 was only obtained for nine of the ten patients.

LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023

Retrieved on: 
Wednesday, October 25, 2023
Lecanemab, Alzheimer's disease, BEST, AD, Biogen, Health care, TIME, Pathology, Co-promotion, HIV disease progression rates, Dementia, Eisai, Disease, AI, Patient, Pharmaceutical industry

TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.

Key Points: 
  • TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.
  • TIME's annual list of THE BEST INVENTIONS features "200 extraordinary innovations changing lives."
  • TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.
  • We will deliver LEQEMBI to the people with early AD who need it and their families, and aim to continue creating impact on global issues surrounding dementia.

Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients

Retrieved on: 
Wednesday, October 25, 2023
Randomness, AD, ADAS, Data, Dementia, Hypoglycemia, Disease, MMSE, Political moderate, Amyloid, Diagnosis, CDR, Patient, Cognition, Insulin, Medical imaging, Pharmaceutical industry

A significant change from baseline was observed in the Amyloid β 42/40 ratio and Amyloid Probability Score as shown by the PrecivityAD® tests from C2N Diagnostics.

Key Points: 
  • A significant change from baseline was observed in the Amyloid β 42/40 ratio and Amyloid Probability Score as shown by the PrecivityAD® tests from C2N Diagnostics.
  • Increased FDG-PET SUVRs were observed in 10 out of 21 patients in a brain imaging sub-study, which is suggestive of reduced amyloid burden.
  • The Company expects to announce unblinded, topline data from this trial in late November or early December.
  • The blinded data presented suggest that NE3107 is a biologically active compound exerting potential effects as observed by biomarker, imaging, cognitive and functional assessments.

Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease

Retrieved on: 
Wednesday, October 25, 2023
Amyloid, Alzheimer's disease, Paper, Dementia, AD, Plaque, Therapy, Neuron, Data, MD, Pathology, IL-6, Cytokine, Doctor of Philosophy, Deficit spending, CNS, McGill University, DSM-IV codes, BDNF, Laboratory, Disease, Caregiver, Neurobiology of Aging, Clinical trial, Rett syndrome, SIGMAR1, Parkinson's disease, Brain, Safety, Patient, Neuroscience, Hippocampus, Central nervous system, Medical device, Pharmaceutical industry, Medical imaging, Ageing

NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, today reported a new peer-reviewed publication in the journal Neurobiology of Aging, titled “Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology”, featuring the orally available small molecule ANAVEX®3-71 (AF710B).1

Key Points: 
  • Preventative treatment with ANAVEX®3-71 reduced levels of insoluble and soluble amyloid-beta as well as plaque deposition in the aging cortex and hippocampus, areas heavily impacted by AD.
  • Notably, the reduction in amyloid pathology was accompanied by a reduction in inflammatory glial activity which is connected to the disease cascade in AD and other dementias.
  • ANAVEX®3-71 treatment downregulated the proinflammatory IL-1β and IL-6 cytokines, which are known to be associated with AD.
  • This long-lasting effect was also observed in previous animal studies of ANAVEX®3-71 at advanced stages of the disease.

LeddarTech Unveils LeddarCar at Reuters Automotive USA 2023 on November 8-9 in Detroit, Demonstrating Next-Gen Sensor Fusion and Perception Software for ADAS Applications

Retrieved on: 
Wednesday, October 25, 2023
AD, ADAS, Original equipment manufacturer, RIDE, Automotive industry, Advanced driver-assistance system, Television

QUEBEC CITY, Oct. 25, 2023 (GLOBE NEWSWIRE) -- LeddarTech ®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, is pleased to announce its participation as a speaker and on-site exhibitor along with demonstrating its technology live with the LeddarCar at the Automotive USA 2023 conference on November 8-9, Huntington Place, Detroit, MI.

Key Points: 
  • QUEBEC CITY, Oct. 25, 2023 (GLOBE NEWSWIRE) -- LeddarTech ®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, is pleased to announce its participation as a speaker and on-site exhibitor along with demonstrating its technology live with the LeddarCar at the Automotive USA 2023 conference on November 8-9, Huntington Place, Detroit, MI.
  • The Automotive USA 2023 event has become an industry hallmark, and this year’s edition promises to be a new milestone in automotive innovation.
  • November 8-9: EXPERIENCE LeddarTech’s award-winning interactive dashboard demonstration at booth #18 featuring LeddarVision, a high-performance, scalable, cost-efficient automotive low-level sensor fusion and perception software solution that is also hardware and processor-agnostic.
  • Also featuring LeddarVision-inspired ADAS products:
    RIDE ALONG LeddarCar live: Delegates representing automotive Tier 1-2 suppliers and OEMs are invited to book a real-world on-road demonstration of LeddarTech’s LeddarVision low-level fusion and perception software technology.